Alembic Pharmaceuticals Ltd has informed BSE regarding a Press Release dated December 09, 2015 titled "Rhizen Pharmaceuticals announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma Inhibitor".
For Quick Alerts
For Daily Alerts
For investment related articles, business news and mutual fund advise
You have already subscribed